drugset / Trial / NCT03894891
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research is being performed to treat patient for head and neck cancer patients who have not received prior chemotherapy.
Timeline
- Start
- 2019-06-11
- Primary completion
- 2022-10-31
- Completion
- 2022-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 100 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |